Elizabeth Hurlburt net worth and biography

Elizabeth Hurlburt Biography and Net Worth

EVP of CorMedix

Liz Masson Hurlburt serves as our EVP, Chief Clinical Strategy and Operations Officer. Prior to that, she held several progressive management roles in clinical operations, most recently at Gemphire Therapeutics, as Vice President, Clinical Operations. Responsible for strategic and clinical development activities, Liz has a passion for growing and developing highly engaged teams and assuring the highest standards for medical affairs and clinical development execution. Liz received her B.A. in Leadership and Organizational Management from Bay Path College and a Master’s in Management and Leadership from Western Governors University.

What is Elizabeth Hurlburt's net worth?: The estimated net worth of Elizabeth Hurlburt is at least $1.37 million as of September 9th, 2025. Hurlburt owns 176,990 shares of CorMedix stock worth more than $1,368,133 as of May 6th. This net worth approximation does not reflect any other investments that Hurlburt may own. Learn More about Elizabeth Hurlburt's net worth.
How do I contact Elizabeth Hurlburt?: The corporate mailing address for Hurlburt and other CorMedix executives is 300 CONNELL DRIVE SUITE 4200, BERKELEY HEIGHTS NJ, 07922. CorMedix can also be reached via phone at (908) 517-9500 and via email at [email protected]. Learn More on Elizabeth Hurlburt's contact information.
Has Elizabeth Hurlburt been buying or selling shares of CorMedix?: Elizabeth Hurlburt has not been actively trading shares of CorMedix during the past quarter. Most recently, Elizabeth Hurlburt sold 41,121 shares of the business's stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $13.08, for a transaction totalling $537,862.68. Following the completion of the sale, the chief operating officer now directly owns 176,990 shares of the company's stock, valued at $2,315,029.20. Learn More on Elizabeth Hurlburt's trading history.
Who are CorMedix's active insiders?: CorMedix's insider roster includes Alan Dunton (Director), Elizabeth Hurlburt (EVP), Myron Kaplan (Director), Steven Lefkowitz (Director), Erin Mistry (EVP), Joseph Todisco (CEO), and Kaufman Zelnick (Insider). Learn More on CorMedix's active insiders.
Are insiders buying or selling shares of CorMedix?: During the last twelve months, CorMedix insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $275,500.00. During the last twelve months, insiders at the sold shares 8 times. They sold a total of 253,997 shares worth more than $3,258,817.44. The most recent insider tranaction occured on December, 30th when Director Alan W Dunton sold 20,000 shares worth more than $260,000.00. Insiders at CorMedix own 3.1% of the company. Learn More about insider trades at CorMedix.
Information on this page was last updated on 12/30/2025.

Elizabeth Hurlburt Insider Trading History at CorMedix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/11/2025	Sell	41,121	$13.08	$537,862.68	176,990
9/9/2025	Sell	12,876	$13.51	$173,954.76	176,990
11/14/2024	Sell	140,027	$11.18	$1,565,501.86	45,397

Elizabeth Hurlburt Buying and Selling Activity at CorMedix

CorMedix Company Overview

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Today's Range

Now: $7.73

$7.68

$7.93

50 Day Range

MA: $7.00

$6.25

$7.82

2 Week Range

Now: $7.73

$6.13

$17.43

Volume

846,199 shs

Average Volume

947,436 shs

Market Capitalization

$606.34 million

P/E Ratio

3.87

Dividend Yield

N/A

Beta

1.46